Clinical Trial Update: VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating VIR-2218 in combination with Peginterferon alfa-2a for Chronic Hepatitis B is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Peginterferon alfa-2a (peginterferon alfa-2a)
• VIR-2218

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Chronic Hepatitis B | Phase 2 | Status: RECRUITING